Watching ‘AF’ter the Heart: the WATCHMAN TM device for atrial fibrillation

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and a leading cause of cardioembolic stroke. In nonvalvular atrial fibrillation (NVAF), thrombus formation occurs predominantly within the left atrial appendage (LAA), making it a key therapeutic target. While oral anticoagulation remains standard for thromboembolic risk reduction, contraindications, elevated bleeding risk, and therapy intolerance drive the need for nonpharmacologic alternatives. This review examines the role of the WATCHMAN left atrial appendage occlusion (LAAO) device in NVAF-related stroke prevention, encompassing pathophysiologic rationale, device design, procedural technique, clinical evidence, post-implantation management, and outstanding evidence gaps. The PROTECT AF and PREVAIL trials established WATCHMAN-based LAAO as noninferior to warfarin for prevention of stroke, systemic embolism, and cardiovascular death, though early procedural complications underscored the importance of operator experience. Subsequent real-world registries confirmed safety and effectiveness in higher-risk, anticoagulation-ineligible populations. Newer-generation platforms including the WATCHMAN FLX and FLX Pro, demonstrate improved sealing performance and procedural safety, while contemporary randomized trials further define LAAO's role relative to DOAC therapy. WATCHMAN-based LAAO represents an important alternative for carefully selected patients, particularly those with high bleeding risk. Optimal patient selection, antithrombotic regimens, and long-term outcomes warrant continued investigation. Atrial fibrillation (AF) is an irregular heart rhythm that significantly raises the risk of stroke. In most patients, this happens because blood clots form in a small pouch in the heart called the left atrial appendage (LAA). Blood thinners are usually prescribed to prevent these clots from traveling to the brain, but many patients cannot safely take blood thinners due to a high risk of serious bleeding or other medical reasons. For these patients, a small device called WATCHMAN can be implanted to physically seal off the LAA, preventing clots from escaping and causing a stroke. The procedure is minimally invasive, performed through a small tube inserted via a vein in the leg and does not require open-heart surgery. Studies have shown that the WATCHMAN device is as effective as blood thinners at preventing stroke, while also reducing the risk of bleeding over time. Newer versions of the device, including the WATCHMAN FLX and FLX Pro, have made the procedure safer and more reliable. After the device is implanted, patients typically take blood-thinning or antiplatelet medications for a short period while the heart tissue grows over the device, after which most patients can stop anticoagulation entirely. While the WATCHMAN device is an important advance for patients who cannot take blood thinners long-term, researchers are still working to identify which patients benefit most and what the best medication plan is after the procedure.